Press Releases

16 February 2024 14:30Ziccum offentliggör utfall i företrädesemissionNewsCorporate ActionSharesIssuanceSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
16 February 2024 14:30Ziccum announces outcome in rights issueNewsCorporate ActionSharesIssuanceEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
12 February 2024 10:45Ziccums VD Ann Gidner i paneldiskussion om mRNA arrangerat av amerikanska Force Family OfficeNewsCorporate InformationOther Corporate InformationSwedishIR
Tack vare etableringen av Ziccum som en nyckelspelare för mRNA i internationell läkemedelsindustri, har Ziccums VD Ann Gidner deltagit i en inspelad paneldebatt, s.k. Fireside chat, med diskussion och inblickar i mRNA-fältet, dess rekordsnabba...
12 February 2024 10:45Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family OfficeNewsCorporate InformationOther Corporate InformationEnglishIR
Based on the growing reputation that Ziccum is building in the international pharmaceutical industry, Ziccum CEO Ann Gidner has taken part in a recorded Fireside Chat reviewing the mRNA arena, its tremendous growth, and the shortcomings of the RNA/LNP...
9 February 2024 09:00Sista dag för handel med uniträtter i ZiccumNewsCorporate InformationOther Corporate InformationSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
9 February 2024 09:00Last day for trading in unit rights in ZiccumNewsCorporate InformationOther Corporate InformationEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
Den 22e januari meddelade Ziccum att finansiering till 2025 säkrats genom en kombinerad riktad emission och företrädesemission. Teckningskursen per Unit i Företrädesemissionen uppgår till 6,80 SEK och varje Unit består...
On January 22, Ziccum announced that financing until 2025 had been secured through a combined directed issue and rights issue. The subscription price per Unit in the Rights Issue amounts to SEK 6.80 and each Unit consists of one (1) share and one (1)...
5 February 2024 10:50Ziccum CEO videointervju: mRNA i fokusNewsCorporate InformationOther Corporate InformationSwedishIR
I en intervju på svenska med Ziccums vd Ann Gidner, diskuteras företagets nya in vivo mRNA-data in-vivo, mRNA-teknologin och dess marknadspotential, samt hur Ziccums teknologi kan lösa viktiga stabilitets- och leveransutmaningar som finns...
5 February 2024 10:50Ziccum CEO video interview: mRNA in focusNewsCorporate InformationOther Corporate InformationEnglishIR
In an interview in Swedish, Ziccum CEO Ann Gidner discusses the company's new in vivo mRNA data, the mRNA market potential and technology and how Ziccum's LaminarPace can solve crucial stability and delivery challenges that can help unlock the full potential...
Ziccums VD, Ann Gidner, presenterar bolagets unika torkningsteknologi för biologiska läkemedel samt bolagets nyligen publicerade och banbrytande mRNA-data. Detta live-evenemang hålls digitalt med Investor Target. Deltagare kan ställa...
3 February 2024 12:20Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6thNewsCorporate InformationOther Corporate InformationEnglishIR
Join Ziccum CEO Ann Gidner on Tuesday 6 February for ‘Invest live’ as she presents Ziccum’s unique technology for biopharmaceuticals and its ground-breaking new mRNA data at a live digital event with Investor Target. Participants may...
1 February 2024 19:02Ziccums Q4-rapport – VD-uppdatering på svenskaNewsCorporate InformationOther Corporate InformationSwedishRegulatoryListing RegulationIR
Vår VD Ann Gidner svarar på frågor om de viktigaste delarna i bolagets senaste kvartalsrapport, Bokslutskommunikén 2024. F: Vilka höjdpunkter vill du lyfta fram? Vad är mest intressant för investerare att fokusera...
31 January 2024 17:48Ziccum has proven excellent mRNA activity in animal study with LaminarPace materialNewsCorporate InformationOther Corporate InformationEnglishRegulatoryMARIR
Ziccum AB (publ) has performed an animal study, confirming excellent genetic activity of mRNA/LNP materials treated by LaminarPace. The in-vivo data confirms the ability of Ziccum’s LaminarPace technology to transform delicate mRNA/LNP liquid solution...
31 January 2024 08:30Ziccums VD i videointervju med EucapsNewsCorporate InformationOther Corporate InformationSwedishIR
Se Ziccums VD Ann Gidner i en ny videointervju på svenska med Eucaps analytiker Jonathan Furelid. Hon delar med sig av insikter om företagets nya mRNA-resultat, deltagande på mRNA Summit och finansieringen med den nya amerikanska investeraren...
30 January 2024 13:45Ziccum launches IR calendar for coming weeksNewsCorporate InformationOther Corporate InformationEnglishRegulatoryListing RegulationIR
Ziccum has a schedule of coming IR activities, following the release of its Information Memorandum on 30 January which followed the announcement on 22 January of a new combined financial package that includes secured financing, a directed share issue...
30 January 2024 10:00Ziccum offentliggör informationsmemorandum med anledning av förestående företrädesemission av unitsNewsCorporate ActionSharesIssuanceSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
30 January 2024 10:00Ziccum publishes Information Memorandum in connection with the forthcoming rights issue of unitsNewsCorporate ActionSharesIssuanceEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
26 January 2024 08:30ZICCUM AB (publ) Year-End report Q4 2023NewsEnglishRegulatoryListing RegulationReportInterimYearendIR
YEAR-END REPORT Q4 2023: 1 JANUARY – 31 DECEMBER 2023 Significant events during the Quarter Significant events after the Quarter CEO statementTaking Ziccum ahead towards new achievements, delivering milestones at a high pace2023 has been an amazing...
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...